Mike has responsibility for growing venture investment transactions and managing equity investments aligned with future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Anjarium Biosciences, Autobahn Therapeutics, Capstan Therapeutics, ImCheck Therapeutics, ImmunOs Therapeutics, Interius Biotherapeutics, Mediar Therapeutics, Parthenon Therapeutics, and TRex Bio.From 2017-2018 Mike served as Senior Director of Portfolio Strategy, critically assessing the R&D portfolio from a volume, value, quality, risk and productivity perspective with the ultimate objective of maximizing R&D productivity and value generation.  From 2011-2017 Mike was Senior Director, Scientific Affairs for the R&D President’s Office, enabling and communicating the R&D strategic agenda as well as leading colleague development capabilities. Mike joined Pfizer in 2008 in the market access space providing strategic and analytical support around marketing and managed care contracting with commercial and government payers.  Previously, Mike worked within the NIH Protein Structure Initiative’s Northeast Structural Genomics Consortium coordinating protein structure production efforts, including bioinformatics, protein expression/purification and 3D structure determination.  Mike is also a co-founder of Nexomics Biosciences, a NJ-based biotechnology company focused on providing gene-2-structure services as well as early-stage drug target validation.  Mike earned his PhD from Robert Wood Johnson Medical School/Rutgers, the State University of New Jersey in biochemistry. He holds a MBA from Rutgers Business School and received his BS in Biochemistry/Information Technology from Syracuse University.